首页|不同剂量左甲状腺素钠片治疗妊娠期甲状腺功能减退的临床效果

不同剂量左甲状腺素钠片治疗妊娠期甲状腺功能减退的临床效果

扫码查看
目的 探讨不同剂量左甲状腺素钠片治疗妊娠期甲状腺功能减退(甲减)的临床效果.方法 100例单胎且确诊为妊娠期甲减患者,根据随机数字表法分为对照组和研究组,各50例.对照组采用低剂量左甲状腺素钠片治疗,研究组采用高剂量左甲状腺素钠片治疗.比较两组患者甲状腺功能[甲状腺过氧化物酶抗体(TPO-Ab)、游离甲状腺素(FT4)、促甲状腺激素(TSH)]、不良妊娠结局发生情况及叶酸、铁蛋白、维生素B12水平.结果 治疗前,对照组患者TPO-Ab为(43.37±3.28)IU/ml,FT4为(6.76±0.14)pmol/L,TSH为(4.69±0.52)mIU/L,研究组患者TPO-Ab为(43.11±3.26)IU/ml,FT4为(6.75±0.18)pmol/L,TSH为(4.71±0.55)mIU/L;治疗后,对照组患者TPO-Ab为(32.02±2.12)IU/ml,FT4为(7.79±0.16)pmol/L,TSH为(2.32±0.22)mIU/L,研究组患者TPO-Ab为(27.31±2.17)IU/ml,FT4为(9.98±0.53)pmol/L,TSH为(1.73±0.23)mIU/L.治疗前,两组患者TPO-Ab、FT4、TSH水平比较,差异不具显著性(P>0.05);治疗后,两组患者的TPO-Ab、TSH水平均较治疗前有所下降,FT4均较治疗前提升,且研究组患者TPO-Ab、TSH水平均低于对照组,FT4水平高于对照组差异具有显著性(P<0.05).对照组患者发生早产3例(6.00%)、胎儿窘迫4例(8.00%)、胎儿生长受限3例(6.00%);研究组患者发生早产2例(4.00%)、胎儿窘迫0例、胎儿生长受限1例(2.00%).研究组患者不良妊娠结局发生率6.00%低于对照组的20.00%(P<0.05).两组患者治疗前后叶酸、铁蛋白及维生素B12水平比较,差异不具有显著性(P>0.05).结论 对于妊娠期甲减患者临床治疗中左甲状腺素钠片剂量的选择,高剂量较低剂量有更为显著的甲状腺功能改善效果,同时可有效预防不良妊娠结局的发生,该治疗方法可供临床治疗参考.
Clinical effects of different doses of levothyroxine sodium tablets on pregnant women with hypothyroidism during pregnancy
Objective To explore the clinical effect of different doses of levothyroxine sodium tablets on pregnant women with hypothyroidism during pregnancy. Methods 100 patients with singleton and diagnosed hypothyroidism during pregnancy were selected as the study subjects. They were divided into a control group and a study group according to random numerical table,with 50 cases in each group. The control group was treated with low-dose levothyroxine sodium tablets,while the study group was treated with high-dose levothyroxine sodium tablets. Comparison was made on thyroid function[thyroid peroxidase antibody (TPO-Ab),free thyroxine (FT4),thyroid stimulating hormone (TSH)],incidence of adverse pregnancy outcomes,folic acid,ferritin,vitamin B12 level between the two groups. Results Before treatment,TPO-Ab of the control group was (43.37±3.28) IU/ml,FT4 was (6.76±0.14) pmol/L,and TSH was (4.69±0.52) mIU/L;TPO-Ab of the study group was (43.11±3.26) IU/ml,FT4 was (6.75±0.18) pmol/L,and TSH was (4.71±0.55) mIU/L. After treatment,TPO-Ab of the control group was (32.02±2.12) IU/ml,FT4 was (7.79±0.16) pmol/L,and TSH was (2.32±0.22) mIU/L;TPO-Ab of the study group was (27.31±2.17) IU/ml,FT4 was (9.98±0.53) pmol/L,and TSH was (1.73±0.23) mIU/L. Before treatment,there was no significant difference in TPO-Ab,FT4 and TSH levels between the two groups (P>0.05). After treatment,the levels of TPO-Ab and TSH decreased and FT4 increased in both groups compared with those before treatment;the levels of TPO-Ab and TSH in the study group were lower than those in the control group,and FT4 level higher than that in the control group;the difference was significant (P<0.05). After treatment,the levels of TPO-Ab and TSH decreased and FT4 increased in both groups,and the magnitude of change in the study group was better than that in the control group;the difference was significant (P<0.05). In the control group,there were 3 cases (6.00%) of premature births,4 cases (8.00%) of fetal distress and 3 cases (6.00%) of fetal growth restriction;in the study group,there were 2 cases (4.00%) of premature births,0 cases of fetal distress,and 1 case (2.00%) of fetal growth restrict ion. The incidence of adverse pregnancy outcome of 6.00% in the study group was lower than 20.00% in the control group (P<0.05). There was no significant difference in the levels of folic acid,ferritin and vitamin B12 between the two groups before and after treatment (P>0.05). Conclusion In the clinical treatment of hypothyroidism during pregnancy,high doses have a more significant effect on improving thyroid function than low doses,and can effectively prevent the occurrence of adverse pregnancy outcomes,the treatment can be used as a reference for clinical treatment.

Hypothyroidism during pregnancyLevothyroxine sodium tabletsDifferent dosesClinical effects

杨瑞琳、郑月明

展开 >

528437 中山火炬开发区人民医院产科

528437 中山火炬开发区人民医院内分泌科

妊娠期甲状腺功能减退 左甲状腺素钠片 不同剂量 临床效果

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(23)